MEI Pharma, Inc.
COMBINATION THERAPIES FOR HIGH AND VERY HIGH RISK MDS
Last updated:
Abstract:
Provided herein are methods of treating high and very high risk MDS comprising administering pracinostat and a DNA hypomethylating agent. S
Status:
Application
Type:
Utility
Filling date:
26 Nov 2019
Issue date:
20 Jan 2022